l3,10,13K7,8K4R2L9

General Information


DRACP ID  DRACP00094

Peptide Name   l3,10,13K7,8K4R2L9

Sequence  KLlRLLkkLlRLlLK

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  Diastereomeric peptide

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
B16-F10 Mouse melanoma Carcinoma LC50=2.5 µM XTT assay 24h 1
D122 Malignant tumors of the mouse pulmonary system Carcinoma LC50=4.5 µM XTT assay 24h 1

Hemolytic Activity  Human erythrocyte: Hemolysis% at 50 μm peptide LC50=0 µM

Normal (non-cancerous) Cytotoxicity  NIH-3T3: LC50=40 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  l=D-Leucine; k=D-Lysine

Chiral  Mix



Physicochemical Information


Formula  C60H106N18O6

Absent amino acids  ACDEFGHIMNPQSTVWY

Common amino acids  L

Mass  142552

Pl  12.53

Basic residues  4

Acidic residues  0

Hydrophobic residues  6

Net charge  4

Boman Index  -1142

Hydrophobicity  40

Aliphatic Index  156

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 12646578

Title  Designed antimicrobial and antitumor peptides with high selectivity

Doi 10.1074/jbc.M211204200

Year  2003

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.